Primary central nervous system lymphoma in a patient treated with natalizumab

Andreas Schweikert; Marcus Kremer; Florian Ringel; Thomas Liebig; Justus Duyster; Olaf Stüve; Bernhard Hemmer; Achim Berthele

doi:10.1002/ana.21782

Primary central nervous system lymphoma in a patient treated with natalizumab

Andreas Schweikert, Marcus Kremer, Florian Ringel, Thomas Liebig, Justus Duyster, Olaf Stüve, Bernhard Hemmer, Achim Berthele

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Abstract

A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out.

Original language	English (US)
Pages (from-to)	403-406
Number of pages	4
Journal	Annals of Neurology
Volume	66
Issue number	3
DOIs	https://doi.org/10.1002/ana.21782
State	Published - 2009

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/ana.21782

Cite this

@article{f3a4263fd3af4ee792b803a451816041,

title = "Primary central nervous system lymphoma in a patient treated with natalizumab",

abstract = "A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out.",

author = "Andreas Schweikert and Marcus Kremer and Florian Ringel and Thomas Liebig and Justus Duyster and Olaf St{\"u}ve and Bernhard Hemmer and Achim Berthele",

year = "2009",

doi = "10.1002/ana.21782",

language = "English (US)",

volume = "66",

pages = "403--406",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Primary central nervous system lymphoma in a patient treated with natalizumab

AU - Schweikert, Andreas

AU - Kremer, Marcus

AU - Ringel, Florian

AU - Liebig, Thomas

AU - Duyster, Justus

AU - Stüve, Olaf

AU - Hemmer, Bernhard

AU - Berthele, Achim

PY - 2009

Y1 - 2009

N2 - A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out.

AB - A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out.

UR - http://www.scopus.com/inward/record.url?scp=70349440918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349440918&partnerID=8YFLogxK

U2 - 10.1002/ana.21782

DO - 10.1002/ana.21782

M3 - Article

C2 - 19798640

AN - SCOPUS:70349440918

SN - 0364-5134

VL - 66

SP - 403

EP - 406

JO - Annals of Neurology

JF - Annals of Neurology

IS - 3

ER -

Primary central nervous system lymphoma in a patient treated with natalizumab

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this